NASDAQ : IBIO
iBio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.8136 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 52.32M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 49.43M |
| Enterprise Value | -36.41M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 64.31M |
| Shares Outstanding | 64.31M |
| Shares Change (YoY) | +891.14% |
| Shares Change (QoQ) | +21.53% |
| Owned by Insiders (%) | 1.32% |
| Owned by Institutions (%) | 37.90% |
| Float | 46.11M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 494.33 |
| Forward PS | 2,965.39 |
| PB Ratio | 0.50 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.85 |
| Quick Ratio | 7.50 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -568.64 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -65.70% |
| Return on Assets (ROA) | -30.80% |
| Return on Invested Capital (ROIC) | -35.42% |
| Return on Capital Employed (ROCE) | -34.50% |
| Weighted Average Cost of Capital (WACC) | 10.77% |
| Revenue Per Employee | $4,348 |
| Profits Per Employee | -$1.44M |
| Employee Count | 23 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -50.08% |
| 50-Day Moving Average | 1.10 |
| 200-Day Moving Average | 1.69 |
| Relative Strength Index (RSI) | 35.27 |
| Average Volume (20 Days) | 870,948 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.73M |
| Short Previous Month | 4.20M |
| Short % of Shares Out | 5.80% |
| Short % of Float | 8.10% |
| Short Ratio (days to cover) | 4.34 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 100,000 |
| Gross Profit | 100,000 |
| Operating Income | -30.14M |
| Pretax Income | -33.04M |
| Net Income | -33.04M |
| EBITDA | -29.49M |
| EBIT | -30.14M |
| Loss Per Share | -$0.32 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 88.04M |
| Total Debt | 2.20M |
| Net Cash | 85.84M |
| Net Cash Per Share | $1.33 |
| Equity (Book Value) | 85.71M |
| Book Value Per Share | 1.54 |
| Working Capital | 80.48M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -23.22M |
| Capital Expenditures | -578,000 |
| Depreciation & Amortization | 646,000 |
| Net Borrowing | -774,000 |
| Free Cash Flow | -23.80M |
| FCF Per Share | -$0.37 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -30,138.00% |
| Pretax Margin | -33,044.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -891.14% |
| Shareholder Yield | -891.14% |
| Earnings Yield | -41.31% |
| FCF Yield | -48.14% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $5.69 |
| Price Target Difference | 640.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | -41.52% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 29, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.07 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |